ATLANTA, GA – – (Globe Newswire – August 29, 2024) – – A shareholder class action lawsuit has been filed against Sage Therapeutics, Inc. (“Sage Therapeutics” or “the Company”) (NASDAQ: SAGE). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects, including allegations that: (i) zuranolone was less effective in treating major depressive disorder (“MDD”) than Defendants had led investors to believe; (ii) accordingly, the FDA was unlikely to approve the Zuranolone new drug application (“NDA”) for the treatment of MDD in its present form, and zuranolone’s clinical results for MDD, as well as its overall regulatory and commercial prospects, were overstated; (iii) SAGE-718 was less effective in treating mild cognitive impairment (“MCI”) due to Parkinson’s Disease (“PD”) than Defendants had led investors to believe; (iv) accordingly, SAGE-718’s clinical, regulatory, and commercial prospects as a treatment for MCI due to PD were overstated; (v) SAGE-324 was less effective in treating essential tremor (“ET”) than Defendants had led investors to believe; and (vi) accordingly, SAGE-324’s clinical, regulatory, and commercial prospects as a treatment for ET were overstated.

If you bought shares of Sage Therapeutics between April 12, 2021 and July 23, 2024, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/sage-therapeutics/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is October 28, 2024.